Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a hemin (heme derivative) presented as a lyophilized powder for solution for injection for intravenous use. It provides exogenous heme to patients with acute intermittent porphyria and other acute hepatic porphyrias, helping to control metabolic crises during an attack.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides cold‑chain logistics where required.

Normosang (human hemin) is used in the management of acute porphyria attacks by supplying heme to down‑regulate the porphyrin synthesis pathway. - Acute intermittent porphyria: reduces the severity and duration of acute neurovisceral attacks. - Acute hepatic porphyria (other types): helps control metabolic decompensation during crises. - Porphyria‑induced neuropathy: alleviates neurological symptoms associated with acute attacks.

Administration of Normosang may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Fever or chills - Nausea or vomiting - Headache - Injection site pain or erythema - Muscle cramps - Elevated liver enzymes

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Hemolysis in patients with G6PD deficiency - Acute renal failure - Coagulopathy or bleeding disorders - Thrombophlebitis at infusion site - Severe hypotension

Prior to prescribing Normosang, clinicians should consider several precautionary measures to ensure safe use. - Assess hepatic function: evaluate liver enzymes before and during therapy. - Screen for G6PD deficiency: avoid use in patients with known deficiency. - Monitor for hypersensitivity: observe for signs of allergic reaction during infusion. - Check renal function: adjust use in patients with impaired kidney function. - Avoid concurrent use with porphyrin‑inducing drugs: review medication list for potential inducers. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Porphyrin‑inducing agents (e.g., barbiturates, sulfonamides): may counteract therapeutic effect. - Anticoagulants (e.g., warfarin): increased risk of bleeding due to heme‑related effects.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., carbamazepine, phenytoin): may alter heme metabolism. - Oral contraceptives: potential to influence porphyrin synthesis. - Vitamin D analogues: monitor calcium levels. - High‑dose iron supplements: may affect heme balance.